Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLARIS: Mazindol ER in Narcolepsy
NCT04923594Phase 2Completed
- Sponsor
- NLS Pharmaceutics AG
- Start
- Sep 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in narcolepsy comparing NLS-2 with Placebo (2 arms). Primary endpoint: Epworth Sleepiness Scale at 4 weeks. Started Sep 2021; status: completed.
02
Drugs
Mazindol ER
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT04923594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04923594.